We are live on ! Find out more
VF

Virtu Financial Portfolio holdings

AUM $2.41B
1-Year Est. Return 48.35%
This Fund
S&P 500
This Quarter Est. Return
+9.52%
1 Year Est. Return
+48.35%
3 Year Est. Return
+116.81%
5 Year Est. Return
+139.6%
10 Year Est. Return
AUM
$1.26B
AUM Growth
+$258M
Cap. Flow
+$193M
Cap. Flow %
15.3%
Top 10 Hldgs %
36.86%
Holding
2,288
New
1,062
Increased
238
Reduced
222
Closed
745

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$22.9M
2
NFLX icon
Netflix
NFLX
+$14.7M
3
SNOW icon
Snowflake
SNOW
+$12.4M
4
LLY icon
Eli Lilly
LLY
+$8.58M
5
CRM icon
Salesforce
CRM
+$8.44M

Sector Composition

Rank Sector Weight
1 Communication Services 24.46%
2 Financials 17.08%
3 Technology 7.74%
4 Healthcare 6.69%
5 Consumer Discretionary 6.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HIO
1101
Western Asset High Income Opportunity Fund
HIO
$340M
$72K 0.01%
+18,582
New +$69.4K
LOMA
1102
Loma Negra
LOMA
$1.16B
$72K 0.01%
+10,139
New +$64.6K
STRO icon
1103
Sutro Biopharma
STRO
$415M
$72K 0.01%
+1,677
New +$53.2K
ULBI icon
1104
Ultralife
ULBI
$119M
$72K 0.01%
+10,489
New +$86.1K
VERU icon
1105
Veru
VERU
$47.6M
$72K 0.01%
+9,934
New +$88.1K
EBS icon
1106
Emergent Biosolutions
EBS
$228M
$71K 0.01%
29,556
+12,623
+75% +$29.7K
EDF
1107
Virtus Stone Harbor Emerging Markets Income Fund
EDF
$170M
$71K 0.01%
+16,395
New +$67.6K
MXCT icon
1108
MaxCyte
MXCT
$133M
$71K 0.01%
+15,161
New +$59K
SUPV
1109
Grupo Supervielle
SUPV
$733M
$71K 0.01%
17,449
+3,166
+22% +$8.64K
NVOS
1110
DELISTED
Novo Integrated Sciences, Inc. Common Stock
NVOS
$71K 0.01%
+86,197
New +$175K
CINT icon
1111
CI&T Inc
CINT
$468M
$70K 0.01%
+13,309
New +$69.8K
HRTX icon
1112
Heron Therapeutics
HRTX
$61.5M
$70K 0.01%
41,237
+25,608
+164% +$28.2K
MTLS
1113
Materialise
MTLS
$398M
$70K 0.01%
+10,611
New +$62.7K
API
1114
Agora
API
$395M
$69K 0.01%
26,088
+7,694
+42% +$21.5K
FOSL icon
1115
Fossil Group
FOSL
$310M
$69K 0.01%
+47,593
New +$69.9K
MBOT icon
1116
Microbot Medical
MBOT
$113M
$69K 0.01%
42,046
+18,138
+76% +$24.2K
PRQR icon
1117
ProQR Therapeutics
PRQR
$271M
$69K 0.01%
+34,904
New +$53.6K
FCO
1118
DELISTED
abrdn Global Income Fund
FCO
$68K 0.01%
+10,451
New +$63.7K
OM icon
1119
Outset Medical
OM
$90.6M
$68K 0.01%
+843
New +$68.6K
PASG icon
1120
Passage Bio
PASG
$14.5M
$68K 0.01%
+3,385
New +$46.7K
WRN
1121
Western Copper and Gold
WRN
$553M
$68K 0.01%
+51,196
New +$65.2K
ARAY icon
1122
Accuray
ARAY
$34.6M
$67K 0.01%
+23,557
New +$64.3K
MFG icon
1123
Mizuho Financial
MFG
$127B
$67K 0.01%
+19,538
New +$66.4K
ORGO icon
1124
Organogenesis Holdings
ORGO
$243M
$67K 0.01%
+16,309
New +$45.7K
SGMT icon
1125
Sagimet Biosciences
SGMT
$592M
$67K 0.01%
+12,301
New +$58K

Similar funds

Virtu Financial's Q4 2023 Portfolio in Review

As of Q4 2023, Virtu Financial held 2,288 positions worth $1.26B, up 26% from $1.01B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Virtu Financial deployed $193M of net new capital in Q4 2023, opening 1,062 new positions and adding to 238 existing holdings. Its largest new stake was State Street Technology Select Sector SPDR ETF: 304,340 shares worth $29.3M.

By sector, the portfolio is most concentrated in Communication Services at 24% of assets, up from 18% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Microsoft, an estimated $22.9M trimmed.

  • Virtu Financial's largest Q4 2023 buy was State Street Technology Select Sector SPDR ETF: 304,340 shares worth $29.3M.
  • Virtu Financial added most to Alphabet (Google) Class A in Q4 2023, an estimated $109M increase.
  • Virtu Financial's biggest Q4 2023 reduction was Microsoft, cutting an estimated $22.9M.
  • Virtu Financial fully exited Eli Lilly in Q4 2023, selling an estimated $8.58M.
  • Virtu Financial's ten largest holdings make up 37% of its $1.26B portfolio in Q4 2023.
  • Virtu Financial opened 1,062 new positions and closed 745 in Q4 2023.
  • Virtu Financial's portfolio value rose 26% quarter-over-quarter to $1.26B.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.